Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Cannabinoids like THC activate CB1 receptors located near the chemoreceptor trigger zone and emetic center. This activation inhibits the release of serotonin and other neurotransmitters responsible for vomiting signals. By blocking neurotransmission of vomiting stimuli, cannabinoids effectively prevent the vomiting reflex triggered by chemotherapy.

Dronabinol (Marinol) and nabilone (Cesamet) are the two FDA-approved synthetic cannabinoid agonists for chemotherapy-induced nausea and vomiting. Both are administered orally and act rapidly within one hour. Dronabinol is given before chemotherapy with optional repeat doses every 2-4 hours, while nabilone is typically dosed the night before, during, and after treatment.

Dronabinol undergoes extensive first-pass hepatic metabolism after oral administration, which significantly reduces its bioavailability. Although the drug is highly lipid-soluble and rapidly absorbed, the liver metabolizes much of it before it reaches systemic circulation, limiting the amount of active drug available to produce therapeutic effects.

Cannabinoid agonists can cause dizziness, dry mouth, euphoria, anxiety, postural hypotension, and tachycardia. Some patients may also experience acute intoxication and psychosis. These side effects occur because CB1 receptors are distributed throughout the central nervous system, affecting multiple physiological systems beyond nausea control.

CB1 receptors are predominantly located in and around the chemoreceptor trigger zone and emetic center, regions critical for initiating the vomiting reflex. THC also blocks serotonin receptor activity in the dorsal vagal complex, another key area involved in nausea and vomiting signaling. These strategic locations make CB1 an attractive drug target for anti-emetic therapy.

THC is a naturally occurring phytocannabinoid extracted from marijuana, while dronabinol and nabilone are synthetic agonists designed to mimic THC's effects. All three activate CB1 receptors to inhibit vomiting signals, but the synthetic versions offer standardized dosing, controlled formulations, and FDA approval for clinical use in chemotherapy patients.

THC inhibits serotonin release in the dorsal vagal complex, a brain region involved in nausea pathways. By reducing serotonin availability, cannabinoids prevent serotonin from activating receptors that would otherwise trigger vomiting. This dual mechanism—CB1 activation and serotonin inhibition—makes cannabinoids effective for managing chemotherapy-induced nausea and vomiting.